|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-09-11 pm EDT
|
5-day change | 1st Jan Change | ||
| 18.96 SEK | -0.42% |
|
+8.34% | -16.11% |
| Sep. 07 | Synact surged in Stockholm, the OMXS30 index rose 0.2 percent | FW |
| Sep. 07 | Rejlers slides on merger plans, OMXS30 index up 0.3 percent | FW |
| Market Cap | 1.06B 110M 94.41M 89.39M 81.03M 152M 10.47B 153M 408M 5.33B 412M 402M 16.83B | P/E 2026 * |
-11.3x | P/E 2027 * | -19.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.09B 112M 96.62M 91.48M 82.92M 156M 10.71B 156M 418M 5.45B 421M 412M 17.22B | EV / Sales 2026 * |
24.6x | EV / Sales 2027 * | 52.6x |
| Free-Float |
68.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| SYNACT | Delayed | |
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| 8F8 | Delayed | |
|
Börse Stuttgart
| 8F8 | Delayed | |
|
CBOE
| Real-time | ||
|
Tradegate
| 8F8 | Real-time | |
|
Boerse Muenchen
| 8F8 | Real-time |
Last Transcript : SynAct Pharma AB
| 1 day | -0.42% | ||
| 1 week | +8.34% | ||
| Current month | -5.20% | ||
| 1 month | +2.16% | ||
| 3 months | +30.40% | ||
| 6 months | +4.52% | ||
| Current year | -16.11% |
| 1 week | 17.2 |  | 20.05 |
| 1 month | 16.84 | | 22.45 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 28.5 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.8 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 2013-12-31 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 2026-02-28 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 2024-02-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 2024-03-19 |
Anders Kronborg
CHM | Chairman | 62 | 2024-03-19 |
Sten Scheibye
BRD | Director/Board Member | 74 | 2024-03-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/26 | Sell | Founder | -150,000 | 0.2813% | ||
| 9/2/26 | Sell | Chief Technology Officer | -350,000 | 0.6563% | ||
| 3/10/26 | Buy | Chairman | 2,750 | 0.0052% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.42% | +8.34% | -0.42% | +6.64% | 110M | |
| -0.65% | -2.93% | +47.52% | +87.34% | 1,001B | |
| -0.29% | -3.51% | +48.78% | +63.27% | 642B | |
| +0.83% | +0.26% | +16.76% | +72.52% | 451B | |
| -0.38% | -3.59% | +28.24% | +35.57% | 340B | |
| -0.09% | -13.54% | +10.08% | +26.87% | 263B | |
| -0.43% | -2.48% | -2.07% | +11.48% | 247B | |
| -1.34% | -13.70% | +33.47% | +44.18% | 207B | |
| -3.44% | -7.51% | -20.08% | -59.58% | 197B | |
| -0.75% | -4.82% | +21.94% | +86.55% | 180B | |
| Average | -0.70% | -4.08% | +18.42% | +37.48% | 352.64B | |
| Weighted average by Cap. | -0.52% | -4.33% | +29.80% | +55.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 44.25M 4.57M 3.93M 3.73M 3.38M 6.34M 436M 6.37M 17.02M 222M 17.15M 16.77M 701M | 21.6M 2.23M 1.92M 1.82M 1.65M 3.09M 213M 3.11M 8.31M 108M 8.37M 8.19M 342M |
| Net income | -47.08M -4.86M -4.19M -3.96M -3.59M -6.74M -464M -6.78M -18.11M -236M -18.25M -17.85M -746M | -31.92M -3.29M -2.84M -2.69M -2.44M -4.57M -315M -4.59M -12.27M -160M -12.37M -12.1M -506M |
| Net Debt | 24.81M 2.56M 2.21M 2.09M 1.89M 3.55M 245M 3.57M 9.54M 124M 9.62M 9.41M 393M | 74.22M 7.66M 6.6M 6.25M 5.66M 10.63M 732M 10.68M 28.54M 372M 28.77M 28.14M 1.18B |
Employees
8
Sector
Pharmaceuticals
Calendar
Nov. 01
Earnings release - Q3 2026
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | SEK 18.96 | -0.42% | 105,457 |
| 26-09-10 | SEK 19.04 | -0.73% | 96,715 |
| 26-09-09 | SEK 19.18 | -2.44% | 123,379 |
| 26-09-08 | SEK 19.66 | +2.08% | 190,369 |
| 26-09-07 | SEK 19.26 | +10.06% | 476,203 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
